Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. NeoHecogenin-3-O-Beta-D-Glycopyranoside has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
The neohecogenin aglycone is a steroid skeleton and behaves like fat in the gut lumen. A lipid vehicle promotes micelle formation and keeps the compound in solution long enough to reach the brush border. This is standard solubility reasoning applied to a poorly water-soluble steroid. No absorption study has been run on this specific glycoside.
The name of the compound states its structure: a neohecogenin core carrying a single beta-D-glucopyranose unit. Intact glycosides of this size are poorly absorbed, and the sugar must come off for the steroid core to cross the intestinal wall. Host lactase-phlorizin hydrolase and bacterial beta-glucosidases both perform this cleavage. That step is established glycoside biochemistry rather than a tested product pairing.
Bacterial deglycosylation in the lower gut is the main route by which plant steroid glycosides become absorbable. People with different microbial populations generate different amounts of free sapogenin from an identical dose. That is a mechanistic reason for inter-individual variation. It is not evidence that adding a probiotic changes any measurable outcome.
A phospholipid emulsifier lowers interfacial tension and keeps a lipophilic steroid dispersed rather than aggregated. Formulators use this to improve the dissolution step that precedes absorption. It is a manufacturing technique with a clear physical basis. Whether it changes systemic exposure of this compound has not been measured.
Free sapogenins are typically conjugated by glucuronidation before excretion. Piperine slows that conjugation in the gut wall and liver, which would raise circulating levels of any substrate. The enzyme inhibition itself is well characterised. Its effect on this specific glycoside is untested, and the same inhibition applies to medications the person may be taking.
Nothing specific on file for NeoHecogenin-3-O-Beta-D-Glycopyranoside. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.